Newsroom | 5838 results

Sorted by: Latest
Neurology
-

Viz.ai soutiendra l'essai MINUTE, une étude multicentrique de référence évaluant la technique SCUBA pour le traitement des hémorragies intracérébrales

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, leader dans la détection des maladies par intelligence artificielle et la coordination intelligente des soins, a annoncé aujourd'hui son soutien à l'essai MINUTE (« Minimally Invasive Neurosurgery Trial for Ultra-early Treatment »), une étude prospective, multicentrique et randomisée évaluant si la technique SCUBA, une approche endoscopique par cathéter permettant l'évacuation ultra-précoce des hémorragies intracérébrales des noyaux gris centraux (BGH), e...
-

Riassunto: Viz.ai supporterà la MINUTE Trial, uno studio seminale, multicentrico, volto a valutare la tecnica SCUBA per il trattamento dell'emorragia intracerebrale

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, il leader nel rilevamento della malattia e nel coordinamento intelligente delle cure basati sull'intelligenza artificiale, oggi ha annunciato il suo supporto del Minimally Invasive Neurosurgery Trial for Ultra-early Treatment (MINUTE), uno studio clinico prospettico, multicentrico, randomizzato, volto a valutare se la tecnica SCUBA, un approccio endoscopico, basato su catetere per l'evacuazione ultra precoce dell'emorragia intracerebrale dei gangli basali...
-

Resumen: Viz.ai colaborará en el ensayo MINUTE, un estudio multicéntrico de referencia que evalúa la técnica SCUBA para el tratamiento de la hemorragia intracerebral

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, líder en la detección de enfermedades con tecnología de IA y en la coordinación inteligente de la atención sanitaria, ha anunciado hoy su apoyo al ensayo Minimally Invasive Neurosurgery Trial for Ultra-early Treatment (MINUTE), un estudio prospectivo, multicéntrico y aleatorizado que evalúa si la técnica SCUBA, un método endoscópico basado en catéteres para la evacuación muy temprana de la hemorragia intracerebral de los ganglios basales (HIB), es una alt...
-

Viz.ai unterstützt die MINUTE-Studie, eine wegweisende multizentrische Studie zur Bewertung der SCUBA-Technik bei der Behandlung intrazerebraler Blutungen

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, der Marktführer im Bereich der KI-gestützten Krankheitserkennung und intelligenten Versorgungskoordination, gab heute seine Unterstützung für die „Minimally Invasive Neurosurgery Trial for Ultra-early Treatment“ (MINUTE)-Studie bekannt, einer prospektiven, multizentrischen, randomisierten Studie, in der untersucht wird, ob die SCUBA-Technik – ein endoskopischer, kathetergestützter Ansatz zur ultrafrühzeitigen Evakuierung intrazerebraler Blutungen in den B...
-

Hemispheric Emerges from Stealth with $52M in Funding to Launch Descartes, the First Frontier NeuroAI Model for Decoding the Human Brain

TEL AVIV, Israel--(BUSINESS WIRE)--Hemispheric, the NeuroAI company building a foundational platform to measure and understand the human brain, emerged today from stealth with $52 million in early-stage funding. The funding comes from leading investors, including Hanaco Ventures, OneMind/Awareness Capital, Protocol Labs, L Catterton, Arkin Capital, Howard Morgan, Naomi Azrieli, Yasmin Lukatz, Scott Belsky, and more. The company was co-founded by Hagai Lalazar, PhD, a computational neuroscientis...
-

Viz.ai to Support the MINUTE Trial, a Landmark Multicenter Study Evaluating the SCUBA Technique for the Treatment of Intracerebral Hemorrhage

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced its support for the Minimally Invasive Neurosurgery Trial for Ultra-early Treatment (MINUTE) Trial, a prospective, multicenter, randomized study evaluating whether the SCUBA technique, an endoscopic, catheter-based approach for ultra-early evacuation of basal ganglia intracerebral hemorrhage (BGH), is a promising alternative to standard medical management to pote...
-

Ionis to hold second quarter 2026 financial results webcast

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, July 29 at 8:30 a.m. Eastern Time to discuss its second quarter 2026 financial results and highlight progress on key programs.The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.About Ionis Pharmaceuticals, Inc.For three decades, Ionis has invented me...
-

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today shared advances across its growing neuroscience portfolio at the Alzheimer’s Association International Conference (AAIC) 2026. This scientific progress underscores the potential of RNAi therapeutics to address the needs of patients with debilitating neurological diseases. Mivelsiran: An investigational RNAi therapeutic targeting amyloid precursor protein (APP) in develop...
-

Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced a series of milestones that significantly advance the clinical adoption of blood-based Alzheimer’s testing. Together, these milestones reinforce the growing role of LucentAD® Complete, Quanterix’s five-analyte ATN(I) algorithmic blood test, in helping clinicians evaluate Alzheimer’s disease through a comprehensive, blood-based assessment. The announcements inc...
-

Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared data from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer’s disease. The data, presented at the Alzheimer’s Association International Conference (AAIC) 2026, expand upon previously reported topline results and demonstrate a combination of meaningful clinical effi...